Clinical Trials Sponsored by OM Pharma

Total 8303 results

LEO Pharma

Completed

A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia

Frontal Fibrosing Alopecia

United States
Amolyt Pharma

Completed

AZP-3601 SAD and MAD Study in Healthy Subjects and Patients With Hypoparathyroidism

Chronic Hypoparathyroidism

Hungary, Netherlands
NervGen Pharma

Completed

A Phase I Safety Study of NVG-291 in Healthy Adults

Spinal Cord Injury

Australia
Nasus Pharma

Completed

Bioavailability of Nasal Epinephrine

Anaphylaxis

Israel
LEO Pharma

Completed

Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trials (DELTA3)

Chronic Hand Eczema

Poland, Belgium, Canada, Denmark, Germany, Netherlands, Spain, France, Italy, United Kingdom
Tarsier Pharma

Completed

A Study to Evaluate TRS01 Eye Drops in Participants With Active Non-infectious Anterior Uveitis

Non-infectious Anterior Uveitis

United States
Zealand Pharma

Completed

The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel Syndrome (EASE SBS 4)

Short Bowel Syndrome

Denmark
NewAmsterdam Pharma

Active, not recruiting

Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies (BROADWAY)

Dyslipidemias | Hypercholesterolemia | Familial Hypercholesterolemia | Atherosclerotic Cardiovascular Disease | High Cholesterol

United States, Poland, Denmark, Czechia, China, Netherlands, Japan, Georgia
Tarsier Pharma

Completed

A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma

Uveitic Glaucoma | Non-infectious Anterior Uveitis

United States, Germany, France
Ellipses Pharma

Completed

EP0057 in Combination With Olaparib in Advanced Ovarian Cancer

Ovarian Cancer

United States, United Kingdom, Hungary
Inventiva Pharma

Completed

Phase 2b Study in NASH to Assess IVA337 (NATIVE)

Non-Alcoholic Steatohepatitis (NASH)

United States, Spain, United Kingdom, France, Belgium, Austria, Switzerland, Australia, Germany, Slovenia, Bulgaria, Canada, Czechia, Italy, Mauritius, Poland
LEO Pharma

Completed

Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7 (ECZTRA 7)

Atopic Dermatitis

Belgium, France, Germany, Poland, United Kingdom, Czechia, Spain
Zealand Pharma

Completed

Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS) (EASE SBS 1)

Short Bowel Syndrome

United States, Denmark, Belgium, Germany, France, United Kingdom, Canada, Netherlands, Poland
Enyo Pharma

Completed

Safety, Tolerability, Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH)

Non-alcoholic Steatohepatitis

United States, Belgium, France, Puerto Rico, United Kingdom
Zealand Pharma

Completed

Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism

Congenital Hyperinsulinism

United States, United Kingdom, Israel, Germany
LEO Pharma

Completed

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2) (ECZTRA 2)

Atopic Dermatitis

United States, Denmark, United Kingdom, Korea, Republic of, Canada, Italy, Australia, Poland, Russian Federation
Zealand Pharma

Completed

A Trial to Compare the Efficacy and Safety of 2 Different Batches of Subcutaneous Dasiglucagon in Patients With T1DM

Hypoglycemia | Diabetes Mellitus, Type 1

Canada
Zealand Pharma

Withdrawn

Efficacy and Safety of Dasiglucagon for Treatment of Post-bariatric Hypoglycemia in Roux-en-Y Gastric Bypass (RYGB) Operated Adults

Glucose Metabolism Disorders | Hypoglycemia
Getz Pharma

Completed

Research on Human Insulin rDNA Safety and Efficacy in Patients With Type 2 Diabetes Mellitus (RISE)

Type 2 Diabetes Treated With Insulin | Adverse Drug Event | Effect of Drug

Pakistan
LEO Pharma

Completed

Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2) (DELTA 2)

Chronic Hand Eczema

Belgium, Canada, Denmark, Germany, Netherlands, Poland, Spain
HRA Pharma

Completed

A Study of Use of Ella®, an Emergency Contraceptive, Under Simulated OTC Conditions (LIBRella)

Emergency Contraception

United States
LEO Pharma

Completed

Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 1)

Chronic Hand Eczema

Canada, France, Germany, Italy, Poland, United Kingdom
ERYtech Pharma

Completed

Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC (Trybeca-1)

Pancreatic Adenocarcinoma

United States, United Kingdom, France
ERYtech Pharma

Terminated

Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2)

Triple Negative Breast Cancer

Spain, Belgium, Hungary
AlzeCure Pharma

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of ACD856

Alzheimer Disease | Cognition Disorder

Sweden
AlzeCure Pharma

Completed

Study to Evaluate the Effects of Single Ascending Oral Doses of ACD856 on Safety, Tolerability and Pharmacokinetics

Alzheimer Disease | Cognition Disorder

Sweden
Getz Pharma

Completed

Monitoring Parameters Beyond Glycemic Control: Impact of Sitagliptin on Quality of Life in Type 2 Diabetes Patients (DQOL)

Quality of Life | Type 2 Diabetes | Metformin+Sitagliptin

Pakistan
LEO Pharma

Completed

Cromoglicate in Psoriasis

Psoriasis

Germany
PLx Pharma

Completed

Pharmacodynamic and Pharmacokinetic Study of PL-ASA

Healthy Volunteers

United States
MaaT Pharma

Completed

Safety and Tolerability Evaluation of MaaT033 (CIMON)

Hematologic Diseases | Chemotherapy Effect

France
UCB Pharma

Completed

A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer

Carcinoma | Non-Squamous Non-Small-Cell Lung Cancer

Poland, Russian Federation, Hungary
ERYtech Pharma

Completed

GRASPA Treatment for Patients With Acute Myeloblastic Leukemia (ENFORCE)

Acute Myeloid Leukemia

France
ERYtech Pharma

Completed

GRASPA (Erythrocytes Encapsulating L-asparaginase) in Patients With Relapse of Acute Lymphoblastic Leukemia (GRASPIVOTALL)

Acute Lymphoblastic Leukemia, in Relapse

France, Belgium
LEO Pharma

Completed

A Trial to Compare the Pharmacokinetics of Tralokinumab in Healthy Subjects

Healthy

Germany
LEO Pharma

Completed

Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and Children

Atopic Dermatitis

United States, Canada
AlzeCure Pharma

Completed

Study of Safety, Efficacy, and Pharmacokinetics of Topical ACD440 in Healthy Volunteers

Pain

Sweden
ERYtech Pharma

Completed

Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase) in Elderly Patients With First Line Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia
Tarsier Pharma

Completed

A Study of TRS01 in Participants With Post-surgical Ocular Inflammation

Post Surgical Ocular Inflammation

United States
Zealand Pharma

Completed

A Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570

Healthy

Germany
Kiadis Pharma

Withdrawn

Off-the-shelf NK Cells (KDS-1000) as Immunotherapy for COVID-19

Covid19
LEO Pharma

Completed

Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment in Psoriasis Vulgaris on the Face and Skin Folds

Psoriasis Vulgaris

Croatia, Germany, Poland, Serbia
Genoscience Pharma

Unknown

A Study to Compare the Efficacy of GNS561 Versus Standard of Care in Patients With SARS-CoV-2 (COVID-19) Infection (CureCovid-2019)

COVID-19

France
LEO Pharma

Completed

Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.

Atopic Dermatitis

United States, Canada, Australia
LEO Pharma

Completed

A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities

Actinic Keratosis

Italy
Kiadis Pharma

Terminated

Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor

Lymphoma | Myeloid Leukemia | Myeloproliferative Disorders | Multiple Myeloma | Myelodysplastic Syndrome | Lymphoblastic Leukemia

Canada, Netherlands, Germany, Belgium, United States, Italy, United Kingdom
Kiadis Pharma

Completed

Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome

Canada, Germany, Belgium, United Kingdom
Zealand Pharma

Completed

Evaluation of the Safety, Tolerability and Bioavailability of Dasiglucagon Following Subcutaneous (SC) Compared to IV Administration

Hypoglycemia

Germany
UCB Pharma

Completed

Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab Pegol

Crohn's Disease

United States, Australia, Canada
Getz Pharma

Completed

Direct Acting Anti-Viral's In Chronic HCV Patients

Safety Issues

Pakistan
Zealand Pharma

Completed

Pharmacokinetic Profile of Glepaglutide After a Single Injection in Subjects With Varying Degrees of Renal Function

Renal Impairment

Hungary, Poland

3

Subscribe